Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2026. The report serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADS) |
| Instrument ISIN | US37733W2044 |
| Transaction Price | $50.7400 |
| Transaction Volume | 9.4103 ADS |
| Transaction Date | June 22, 2026 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition event within an executive savings plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. The transaction was executed by Maya Martinez-Davis, President of GSK US, within her GSK Executive Supplemental Savings Plan account.
Key Facts for Investor Verification
- The filing confirms an insider purchase of approximately 9.41 ADS at $50.74 per share on June 22, 2026.
- The transaction was conducted on the NYSE as part of a supplemental savings plan.
- This document does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.